Silence Therapeutics (London, England, www.silence-therapeutics.com) has appointed Jeffrey Scott Vick as Group CEO.
Silence Therapeutics (London, England, www.silence-therapeutics.com) has appointed Jeffrey Scott Vick as Group CEO. With this appointment, the company hopes to strengthen its core management team and expand its business partnerships. Vick has held senior positions in the healthcare industry in both Europe and the US, gaining experience as a business analyst and biotech venture capitalist. He has worked in the drug development sector for five years in senior management roles with DepoTech Corporation.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.